NeuroOne报告2024年产品收入增长77%

2024-12-17 21:52

NeuroOne Medical Technologies (NASDAQ:NMTC) said on Tuesday that its product revenue increased 77% to $3.5 million in fiscal year 2024, compared to $2.0 million in fiscal 2023.
Revenue was lower in Q4 2024 versus a year ago due to NeuroOne’s cancellation of Zimmer Biomet’s order to transition manufacturing to strictly RF ablation-capable electrodes.
Operating expenses decreased 12% to $3.0 million in the fourth quarter of fiscal year 2024.
The company expects product revenue to range between $8 and $10 million in fiscal year 2025, representing an increase of between 132% and 190% when compared to product revenue of $3.5 million in fiscal year 2024.
It expects product gross margin to range between 47% and 51% in fiscal year 2025, compared to product gross margin of 31% in fiscal year 2024.
NeuroOne Medical Technologies (NMTC) shares were up more than 13% in pre-market trading.

More on NeuroOne Medical Technologies